The National Institutes of Health (NIH) intends to award a non-competitive contract to Constant Systems LTD for a high-pressure cell disruptor. This equipment is needed by the National Institute of Diabetes and Digestive and Kidney Diseases for protein purification and membrane biology studies, requiring controlled, reproducible cell disruption. The procurement is conducted under simplified acquisition procedures and is not expected to exceed the simplified acquisition threshold of $350,000. Performance of services will be at the NIH facility in Bethesda, Maryland. Interested parties must submit responses by July 13, 2026, to demonstrate their capability to fulfill the requirement.